Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma

被引：0
|
作者：
Lu, Xinli [1 ]
Qian, Cheng [2 ]
机构：
[1] Pharmacy Intravenous Admixture Services, The First People's Hospital of Ningyang County, Tai'an, Shandong,271400, China
[2] Department of Thyroid and Breast Surgery, Zhuji People's Hospital of Zhejiang Province, Zhejiang,311800, China
来源：
Computational and Mathematical Methods in Medicine | 2022年 / 2022卷
关键词：
Compendex;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patient treatment
引用
收藏
相关论文
共 50 条
  • [31] Serum activin A and response to the aromatase inhibibitor (AI) letrozole versus tamoxifen in metastatic breast cancer
    Jensen, Meghan
    Kang, Ashley
    Ali, Suhail M.
    Leitzel, Kim
    Garg, Ashwani
    Rogerio, Jaqueline
    Chen, David
    Hall, Raymond
    Hofsess, Scott
    Chaudri-Ross, Hilary A.
    Bade, Nicholas
    Carney, Walter P.
    Lipton, Allan
    CANCER RESEARCH, 2015, 75
  • [32] Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial
    Munzone, E.
    Giobbie-Hurder, A.
    Gusterson, B. A.
    Mallon, E.
    Viale, G.
    Thurlimann, B.
    Ejlertsen, B.
    MacGrogan, G.
    Bibeau, F.
    Lelkaitis, G.
    Price, K. N.
    Gelber, R. D.
    Coates, A. S.
    Goldhirsch, A.
    Colleoni, M.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2442 - 2449
  • [33] A Stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy - For advanced breast cancer in postmenopausal patients
    Karnon, J
    Jones, T
    PHARMACOECONOMICS, 2003, 21 (07) : 513 - 525
  • [34] Cost-utility analysis of Palbociclib plus letrozole and ribociclib plus letrozole versus Letrozole monotherapy in the first-line treatment of metastatic breast cancer in Iran using partitioned survival model
    Darvishi, Ali
    Daroudi, Rajabali
    Fazaeli, Ali Akbar
    HEALTH ECONOMICS REVIEW, 2023, 13 (01)
  • [35] Letrozole: advancing hormone therapy in breast cancer
    Lee, Rebecca J.
    Armstrong, Anne C.
    Wardley, Andrew M.
    WOMENS HEALTH, 2012, 8 (06) : 611 - 618
  • [36] Effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole
    Safra, T.
    Molho, R. Bernstein
    Stephansky, I.
    Yaal-Hahoshen, N.
    Inbar, M.
    Ackerstein, A.
    Geffen, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Regression of an asymptomatic choroidal metastasis from breast carcinoma following letrozole therapy
    Yohendran, Jayshan
    Chauhan, Devinder
    AFRICAN VISION AND EYE HEALTH JOURNAL, 2009, 68 (04): : 217 - 220
  • [38] Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer
    Lipton, Allan
    Leitzel, Kim
    Chaudri-Ross, Hilary A.
    Evans, Dean B.
    Ali, Suhail M.
    Demers, Laurence
    Hamer, Peter
    Brown-Shimer, Sheryl
    Pierce, Karen
    Gaur, Victor
    Carney, Walter
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (16) : 2653 - 2658
  • [39] EFFICACY OF LETROZOLE VERSUS CLOMIPHENE CITRATE IN ANOVULATORY INFERTILITY
    Razzaq, Sajeela
    Rasheed, Shahid
    Pansota, Mubasher Saeed
    Fatima, Naheed
    GOMAL JOURNAL OF MEDICAL SCIENCES, 2015, 13 (01): : 15 - 18
  • [40] A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy for advanced breast cancer in postmenopausal patients in Germany
    Fricke, FU
    Quednau, K
    Pirk, O
    VALUE IN HEALTH, 2002, 5 (06) : 443 - 443
12345